USA - NYSEARCA:KAPA - US48301N1046 - Common Stock
Overall KAPA gets a fundamental rating of 2 out of 10. We evaluated KAPA against 534 industry peers in the Biotechnology industry. While KAPA has a great health rating, there are worries on its profitability. KAPA does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.6% | ||
| ROE | -78.56% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.29 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.16 | ||
| Quick Ratio | 7.16 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.14
-0.01 (-0.87%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.94 | ||
| P/tB | 4.04 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.6% | ||
| ROE | -78.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.16 | ||
| Quick Ratio | 7.16 | ||
| Altman-Z | 17.29 |
ChartMill assigns a fundamental rating of 2 / 10 to KAPA.
ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.
KAIROS PHARMA LTD (KAPA) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of KAIROS PHARMA LTD (KAPA) is expected to decline by -20% in the next year.